US OptionsDetailed Quotes
NVNO250117C2500
- 0.70
- +0.10+16.67%
15min DelayTrading Dec 27 12:19 ET
0.70High0.70Low
0.70Open0.60Pre Close10 Volume20 Open Interest2.50Strike Price700.00Turnover634.13%IV3.23%PremiumJan 17, 2025Expiry Date0.60Intrinsic Value100Multiplier21DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.8211Delta0.0541Gamma1.61Leverage Ratio-0.0307Theta0.0004Rho1.32Eff Leverage0.0020Vega
enVVeno Medical Stock Discussion
Accesswire· 5 mins ago
Successful Completion of All Planned Implants in GLP Study
enVVe Delivery System Demonstrates Consistent Performance
Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Monday, 16th December at 8:50 am
Successful Completion of All Planned Implants in GLP Study
enVVe Delivery System Demonstrates Consistent Performance
Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results
IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ: NVNO) ("enVVeno" or the "Company"), a com...
3 MINUTES AGO, 8:15 AM EST
VIA ACCESSWIRE
Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium
Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
enVVeno Medical has submitted its PMA application to the FDA for the VenoValve, seeking marketing and sales approval in the United States. Four out of five modules have been approved, with the final module containing clinical data from the SAVVE pivotal trial and proposed labeling.
The FDA-designated breakthrough device aims to treat severe deep venous Chronic Venous Insufficiency (CVI), ta...
7 MINUTES AGO, 8:30 AM EDT
VIA ACCESSWIRE
First wave of implants successfully completed with updated delivery system performing very well
Company on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public OfferingenVVeno Medical (NASDAQ:NVNO) has announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock (or pre-funded warrants) at $3.50 per share. The company expects to receive gross proceeds of approximately $15.0 millionfrom the offering, excluding underwriting discounts and other expenses. The offering is expected to close around September 30, 2024.
The co...
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
enVVeno Medical has made significant progress in its FDA premarket approval (PMA) application for the VenoValve, a surgical replacement venous valve. The company has successfully submitted, and the FDA has approved, four out of five modules required for the PMA application. The fifth and final module, containing clinical data from the SAVVE U.S. pivotal trial, is expecte...
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
enVVeno Medical announced the presentation of new interim venous ulcer healing data from the VenoValve U.S. pivotal trial at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024. The data, presented by Dr. Cassius Iyad Ochoa Chaar of Yale School of Medici...
No comment yet